NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation
16. Juli 2024 11:15 ET
|
NeOnc Technologies Holdings, Inc.
FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1...
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
26. Juni 2024 16:39 ET
|
NeOnc Technologies Holdings, Inc.
New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous funding round.Financing supports further...
NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’
04. April 2023 14:00 ET
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES and CHICAGO and LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings Inc., a clinical stage medical biotechnology company, announced that its CEO, Thomas Chen, MD,...
NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®
06. März 2023 08:00 ET
|
NeOnc Technologies Holdings, Inc.
Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors.AnovaOS™...
Brain Tumor Treatment Market is expected to accumulate a Value of US$ 5,904.82 Million by registering a CAGR of 7.2% | Future Market Insights, Inc.
24. August 2022 08:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The global brain tumor treatment market is anticipated to showcase an opulent growth opportunity over the estimation period from 2022 to 2032 with a...
Brain Cancer Diagnostics Market Revenue to Cross $7.37 Bn Globally, by 2028 at 28.5.% CAGR - Exclusive Report by The Insight Partners
15. Juli 2022 08:30 ET
|
The Insight Partners
New York, July 15, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Brain Cancer Diagnostic Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by...
First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors
04. Dezember 2019 09:35 ET
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the National Cancer Institute (NCI) has enrolled the first two patients of a...